Trade Mark Journal No.2025/029 18 July 2025

WO0000001861604 (5,44)

Office of origin: United States of America

Date of International Registration:17 April 2025
Date of designation in the UK: 17 April 2025
Image for mark 1861604 ANKTESIS

International priority date claimed: 21 November 2024 (United States of America) (98865900)
Class 5
Cell preparations for medical use in cell therapy for the treatment and prevention of oncologic diseases and disorders, immune-oncologic diseases and disorders, cancer, non-cancerous neoplasia, immunologic dysfunction, immunologic-related diseases, infections, and infectious diseases.
Class 44
Medical services; medical information; providing medical information in the fields of immunotherapy, oncology, cancer, immune-oncology, autoimmune diseases, infectious diseases and human diseases via a website; providing medical information relating to immunotherapy, oncology, cancer, immune-oncology, autoimmune diseases, infectious diseases and human diseases.

ImmunityBio, Inc.

Representative: Alicia M. Passerin Leech Tishman Fuscaldo & Lampl, 525 William Penn Place, 28th Floor, Pittsburgh PA 15219, UNITED STATES OF AMERICA